WO2013055302A9 - Effervescent composition comprising n-acetylcysteine and doxophylline or theophylline - Google Patents
Effervescent composition comprising n-acetylcysteine and doxophylline or theophylline Download PDFInfo
- Publication number
- WO2013055302A9 WO2013055302A9 PCT/TR2012/000082 TR2012000082W WO2013055302A9 WO 2013055302 A9 WO2013055302 A9 WO 2013055302A9 TR 2012000082 W TR2012000082 W TR 2012000082W WO 2013055302 A9 WO2013055302 A9 WO 2013055302A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acetylcysteine
- doxophylline
- theophylline
- effervescent composition
- combining
- Prior art date
Links
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title abstract 2
- 229960004308 acetylcysteine Drugs 0.000 title abstract 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title 2
- 229960004483 doxofylline Drugs 0.000 title 1
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 title 1
- 229960000278 theophylline Drugs 0.000 title 1
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 229940066491 mucolytics Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- -1 xanthine derivative compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical formulations prepared by combining a mucolytic agent N-Acetylcysteine with a xanthine derivative compound, their preparation method and use in treatment of respiratory tract diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2011/04738 | 2011-05-16 | ||
TR2011/04738A TR201104738A2 (en) | 2011-05-16 | 2011-05-16 | Pharmaceutical combination containing N-Acetylcysteine. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013055302A1 WO2013055302A1 (en) | 2013-04-18 |
WO2013055302A9 true WO2013055302A9 (en) | 2013-08-01 |
Family
ID=47430028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2012/000082 WO2013055302A1 (en) | 2011-05-16 | 2012-05-14 | Effervescent composition comprising n- acetylcysteine and doxophylline or theophylline |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR201104738A2 (en) |
WO (1) | WO2013055302A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3184505A (en) | 1962-06-18 | 1965-05-18 | Mead Johnson & Co | Process for the n-monoacylation of cysteine |
IT1113122B (en) | 1978-04-06 | 1986-01-20 | Abc Ist Biolog Chem Spa | PHARMACEUTICAL COMPOSITION WITH ANTIBROCOSPASTIC AND ANTITOSSE ACTIVITIES |
DE2842822C3 (en) * | 1978-09-30 | 1982-05-19 | Merz + Co GmbH & Co, 6000 Frankfurt | Medicinal preparations of poorly soluble medicinal substances in the form of effervescent granules |
CH667590A5 (en) * | 1986-07-24 | 1988-10-31 | Inpharzam Int Sa | WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. . |
EP2130443A1 (en) * | 2008-06-06 | 2009-12-09 | Finzelberg GmbH & Co. KG | Water-soluble extracts of Artemisia dracunculus (tarragon) for improvement of glucose metabolism |
WO2011146031A1 (en) * | 2010-05-18 | 2011-11-24 | Bilgic Mahmut | Pharmaceutical composition comprising n- acetylcysteine and a xanthine |
-
2011
- 2011-05-16 TR TR2011/04738A patent/TR201104738A2/en unknown
-
2012
- 2012-05-14 WO PCT/TR2012/000082 patent/WO2013055302A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2013055302A1 (en) | 2013-04-18 |
TR201104738A2 (en) | 2012-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012021715A3 (en) | Stable formulations of linaclotide | |
IL232267A (en) | (4-phenylimidazol-2 -yl) ethylamine derivatives, pharmaceutical compositions containing same and uses thereof in the treatment of diseases for which inhibition of the nav1.8 sodium channel is indicated | |
IL231536A (en) | Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases | |
MX369121B (en) | Aqueous pharmaceutical formulation of tapentadol for oral administration. | |
EP2340821A4 (en) | Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient | |
PH12017501688A1 (en) | Intranasal benzodiazepine pharmaceutical compositions | |
WO2012037562A3 (en) | Pharmaceutical and nutraceutical compositions of abscisic acid | |
WO2011017502A3 (en) | Linaclotide-containing formulations for oral administration | |
WO2011141488A3 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
WO2012047951A3 (en) | Human lung stem cells and uses thereof | |
HK1199452A1 (en) | Derivatives of 4-hydroxy-1,2,3,4- tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract 4--1234--1- | |
WO2014203275A3 (en) | An improved process for the preparation of apixaban and intermediates thereof | |
WO2013117744A3 (en) | Methods of treating fibrosis | |
TN2016000121A1 (en) | Cyclic thienouracil-carboxamides and use thereof | |
WO2011093818A3 (en) | Pharmaceutical compositions comprising salmeterol and fluticasone | |
WO2011107866A3 (en) | Silyl-derivatives of polysaccharides | |
WO2014027979A3 (en) | Tablet formulations comprising tadalafil and dapoxetine | |
WO2012019428A8 (en) | Benzohydrol derivatives, a preparation process and pharmaceutical use thereof | |
EP2583966A4 (en) | Tricarbonyl technetium-99m or rhenium-188 label ring rgd derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseases | |
CL2013003556A1 (en) | Phthalazinone-pyrrolo [3,2-d] pyrimidine-carboxamide derivatives, phosphodiesterase type 4 and type 5 inhibitors; pharmaceutical composition that comprises or fixed combination, not fixed and kit, use of the compound in the preparation of a medicament for treating respiratory tract diseases | |
WO2013055302A9 (en) | Effervescent composition comprising n-acetylcysteine and doxophylline or theophylline | |
WO2013054364A3 (en) | Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof | |
WO2013072770A3 (en) | Pharmaceutical formulations comprising atorvastatin and glimepiride | |
WO2011093812A3 (en) | Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form | |
EP2431049A4 (en) | Pharmaceutical preparation to be administered into respiratory organs for treating or preventing inflammatory respiratory diseases, and method for treating or preventing such diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12806190 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12806190 Country of ref document: EP Kind code of ref document: A1 |